Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05963932 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05963932 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants.
The verdict
NCT05963932, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact of the BMS-986419 new immediate release (IR) tablet formulation compared to the current enteric (DR) capsule formulation, and to assess the effect of food on the drug levels of the IR tablet formulation in healthy adult participants.
Interventions
- DRUG BMS-986419 DR Capsule
- DRUG BMS-986419 IR Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2023-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05963932
The ClinicalTrials.gov registry entry for NCT05963932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986419 DR Capsule is the first listed.
NCT05963932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05963932 about?
NCT05963932 is a clinical study titled "A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants". The purpose of this study is to assess the impact of the BMS-986419 new immediate release (IR) tablet formulation compared to the current enteric (DR) capsule formulation, and to assess the effect of food on the drug levels of the IR tablet formulation in healthy adult participants.
What is the current status of trial NCT05963932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-08-08. Estimated completion is 2023-10-17.
What interventions are being tested in trial NCT05963932?
The interventions under investigation include: BMS-986419 DR Capsule (DRUG), BMS-986419 IR Tablet (DRUG).
Who is sponsoring clinical trial NCT05963932?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.